DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Harrison SA, Abdelmalek MF, Caldwell S. , et al; GS-US-321-0105 and GS-US-321-0106 Investigators.
Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by non-alcoholic steatohepatitis.
Gastroenterology 2018;
155 (04) 1140-1153
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.